×
About 173 results

ALLMedicine™ Alopecia Totalis Center

Research & Reviews  53 results

Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
https://doi.org/10.1007/s12016-021-08883-0 10.1016/j.jaad.2020.06.047 10.1016/j.jaad.2019.08.032 10.1016/j.jaad.2017.04.1141 10.1007/s40265-020-01293-0 10.1111/exd.14073 10.1016/j.jaut.2018.12.001 10.1111/bjd.16808 10.1016/j.jaci.2019.08.035 10.1111/jdv.15489 10.1016/j.jaci.2017.10.028 10.1016/j.jaad.2017.04.1142 10.1016/j.jaad.2005.12.007 10.1016/s0190-9622(98)70499-2 10.1016/j.jaad.2009.02.006 10.1086/511442 10.1038/nature09114 10.1038/JID.2015.402 10.1038/jid.2012.129 10.1016/j.ebiom.2020.102810 10.1016/j.jisp.2020.04.003 10.1111/exd.13123 10.1111/exd.13986 10.1111/exd.14155 10.1056/NEJMra1103442 10.1016/j.autrev.2016.03.008 10.1111/j.1365-2133.2006.07377.x 10.1111/j.0022-202X.2004.23580.x 10.1038/nm.3645 10.1038/nm.3685 10.1016/j.jaut.2018.04.001 10.1111/jdv.14775 10.1001/jamadermatol.2014.504 10.1159/000350933 10.1111/1346-8138.12978 10.1111/jdv.12932 10.1016/j.alit.2019.07.009 10.1371/journal.pone.0094260 10.1007/s00403-015-1539-1 10.1111/exd.14129 10.1001/jamadermatol.2014.62 10.1016/j.jid.2016.04.004 10.1046/j.0022-202x.2001.01583.x 10.1111/ced.12556 10.5152/balkanmedj.2016.16190 10.1111/ijd.14753 10.1001/jamadermatol.2014.3324 10.1016/j.jaad.2009.04.031 10.4103/0378-6323.102361 10.1111/ced.12471 10.1111/exd.14027 10.1016/j.jaad.2020.06.1026 10.1016/j.jdermsci.2010.03.009 10.1038/nature18848 10.1034/j.1600-0625.2003.120104.x 10.1111/jdv.15885 10.1111/bjd.19461 10.1371/journal.pone.0215206 10.1038/gene.2017.4 10.1016/j.molmed.2011.07.005 10.3389/fimmu.2019.00856 10.1111/j.1365-2133.2011.10646.x 10.1016/j.jid.2017.09.046 10.1002/jcb.28700 10.1016/j.jaad.2018.12.047 10.1007/s12016-017-8620-9 10.1016/j.jaad.2009.05.001 10.5826/dpc.0904a05 10.1159/000249182 10.1016/j.jaad.2008.07.062 10.1016/j.clindermatol.2013.06.003 10.1111/ijd.13866 10.1111/1346-8138.14283 10.1016/j.jaad.2012.02.013 10.4103/0019-5154.84768 10.1159/000490459 10.1016/j.jaad.2011.02.017 10.1016/j.det.2012.08.001 10.1111/1346-8138.12591 10.1111/j.1365-2133.2012.10955.x 10.1111/jdv.15582 10.1016/j.jaad.2006.05.008 10.1111/ajd.12941 10.1159/000442816 10.1016/j.jaad.2018.08.059 10.1111/bjd.18883 10.1111/bjd.19024 10.1007/s40257-020-00545-9 10.1016/j.jaad.2015.04.049 10.1016/j.jaad.2019.11.066 10.1097/00055735-200012000-00016 10.1016/j.jaad.2004.10.873 10.1016/j.jaad.2015.12.026 10.2147/dddt.S214907 10.1111/jdv.15545 10.1111/ijd.14933 10.1001/jamadermatol.2018.2312 10.1007/s13555-018-0226-5 10.1111/exd.13758 10.1016/j.jaad.2019.10.043 10.1016/j.jaad.2019.04.053 10.1016/j.jaad.2015.12.055 10.1111/1346-8138.13933 10.1038/nrrheum.2015.167 10.1016/j.immuni.2012.03.014 10.1016/j.jaad.2016.12.005 10.1038/ncomms6966 10.1172/jci.insight.89776 10.1016/j.jid.2018.01.032 10.1016/j.jaad.2016.09.007 10.1016/j.jaad.2016.09.006 10.1016/j.jaad.2018.08.041 10.1016/j.jaad.2018.12.041 10.1172/jci.insight.89790 10.1016/j.ebiom.2015.02.015 10.1016/j.jdcr.2019.07.005 10.1080/17512433.2020.1702878 10.1007/s40744-020-00258-9 10.1126/sciadv.1500973 10.1111/jdv.15489 10.3389/fimmu.2019.02847 10.1177/120347541201600407 10.1016/j.jaad.2005.03.039 10.1001/archdermatol.2009.264 10.1016/j.jaad.2007.10.645 10.1016/j.jaci.2015.06.032 10.1007/s00403-018-1853-5 10.1016/j.jaad.2020.08.051 10.1111/bjd.18976 10.1016/j.jdcr.2020.10.010 10.1111/bjd.16711 10.1111/jdv.16493 10.1016/j.jdcr.2017.11.020 10.3315/jdcr.2010.1041 10.1684/ejd.2013.2221 10.1016/j.jaci.2015.11.001 10.1111/pde.13699 10.1684/ejd.2020.3866 10.1016/j.jdcr.2019.10.012 10.1159/000499030 10.1007/s40265-014-0218-4 10.1016/j.jdermsci.2014.11.009 10.1080/09546634.2019.1616046 10.1684/ejd.2019.3576 10.1007/s00403-018-1876-y 10.1016/j.jaad.2017.11.056 10.1684/ejd.2020.3749 10.1080/09546634.2019.1589641 10.1016/j.jaad.2017.05.034 10.1038/nrd1989 10.1016/j.jaad.2020.09.091 10.1136/annrheumdis-2016-210724 10.1016/j.jisp.2020.05.002 10.1111/j.1524-4725.2012.02394.x 10.1111/bjd.12397 10.1111/jocd.12858 10.1016/j.jdcr.2015.07.004 10.1111/dth.12989 10.1056/NEJMoa1105143 10.1038/nrd.2018.148 10.1016/j.jid.2020.08.015 10.1016/j.jisp.2017.10.013 10.1016/j.jaad.2020.03.102 10.1016/j.jaad.2014.11.006 10.1159/000468991 10.5021/ad.2017.29.6.755 10.1016/j.jaad.2015.09.071 10.1016/j.jaad.2019.04.047 10.1111/j.1346-8138.2007.00401.x 10.1111/j.1346-8138.2009.00647.x 10.1046/j.1365-2222.2003.01701.x 10.1016/s0002-9394(14)70870-0 10.1111/j.1365-2133.2010.09685.x 10.1111/j.1468-3083.2009.03543.x 10.1016/j.jaad.2009.01.027 10.1016/j.jaad.2008.08.029 10.1159/000371416 10.1080/09546634.2017.1330527 10.1111/pde.12920 10.1016/j.jaad.2017.06.027 10.1159/000494613 10.1016/j.jaad.2017.03.024 10.1016/j.jdcr.2019.07.005 10.1002/acr.24007 10.1002/art.41316
Clinical Reviews in Allergy & Immunology; Zhou C, Li X et. al.

Aug 18th, 2021 - Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse ...

Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia ...
https://doi.org/10.1159/000515764
Dermatology (Basel, Switzerland); Zhang T, Nie Y

May 19th, 2021 - Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients remains unf...

Alopecia areata is not a risk factor for heart diseases: A 10-year retrospective cohort...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104430
PloS One; Lee H, Kim YC et. al.

May 8th, 2021 - Alopecia areata (AA) is an autoimmune skin disease caused by chronic inflammation of hair follicles. Chronic inflammatory skin diseases such as psoriasis and lupus erythematosus can increase the risk of cardiovascular diseases. However, the relati...

Hypotrichosis-lymphedema-telangiectasia syndrome: Report of ileal atresia associated wi...
https://doi.org/10.1002/ajmg.a.62205
American Journal of Medical Genetics. Part A; Coulie R, Niyazov DM et. al.

Apr 15th, 2021 - Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS) is a rare condition caused by pathogenic variants in the SOX18 gene. SOX18 plays a key role in angio- and lymphangiogenesis due to its expression in venous endothelial cells from which the ly...

Alopecia totalis following hand-foot-and-mouth disease.
https://doi.org/10.1111/pde.14550
Pediatric Dermatology; Oska S, Bedford LM et. al.

Mar 3rd, 2021 - We present a case of a 13-month-old male patient with alopecia totalis that began two months after an episode of hand-foot-and-mouth disease. It is hypothesized that the viral infection triggered an autoimmune response, which lead to production of...

see more →

News  16 results

The Case of the Disappearing Eyebrows
https://www.mdedge.com/clinicianreviews/article/195335/dermatology/case-disappearing-eyebrows/page/0/1?channel=203

Feb 28th, 2019 - DISCUSSION This case illustrates several variants of an extremely common condition: alopecia areata (AA), literally translated as “hair loss confined to a particular localized area or areas. ” Although AA is more common in adults, it often affects.

Anthralin shows promise as second-line agent for pediatric alopecia areata
https://www.mdedge.com/pediatrics/article/189807/dermatology/anthralin-shows-promise-second-line-agent-pediatric-alopecia
Jill D. Pivovarov

Nov 29th, 2018 - Given its limited systemic toxicity, topical anthralin is an acceptable second-line treatment option for pediatric alopecia areata (AA), according to Sean Z. Wu, MD, of the department of dermatology, University of Cincinnati, and his associates.

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis
https://www.medscape.com/viewarticle/903234

Oct 10th, 2018 - In addition to effectively treating a resistant case of atopic dermatitis, the eczema drug dupilumab (Dupixent, Regeneron Pharmaceutics) triggered hair growth in a young patient with longstanding alopecia totalis, investigators report. The dual ef...

A new era arrives in alopecia areata therapy
https://www.mdedge.com/dermatology/article/175771/hair-nails/new-era-arrives-alopecia-areata-therapy
Bruce Jancin

Sep 26th, 2018 - PARIS – Each of two oral Janus kinase inhibitors individually showed impressive efficacy and acceptable safety and tolerability for treatment of chronic moderate to severe alopecia areata in a phase 2 study that promises to alter the therapeutic l.

JAK Inhibitors Promising for Alopecia Areata
https://www.medscape.com/viewarticle/902077

Sep 17th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

see more →